Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Cedars-Sinai Medical Center
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
AstraZeneca
Taiho Oncology, Inc.
Revolution Medicines, Inc.
Beth Israel Deaconess Medical Center
Seagen Inc.
Queen Mary University of London
Seagen Inc.
Actuate Therapeutics Inc.
University of Arizona
University of Oklahoma
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
NYU Langone Health
University Medical Centre Ljubljana
Washington University School of Medicine
City of Hope Medical Center
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
CHU de Quebec-Universite Laval
Washington University School of Medicine
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
Astellas Pharma Inc
Tomsk National Research Medical Center of the Russian Academy of Sciences
Institute of Cancer Research, United Kingdom
M.D. Anderson Cancer Center
Hoffmann-La Roche
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University Hospital, Antwerp
University of California, Davis
Erasca, Inc.
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins